Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645980 | 0.86 | NOTUM (0.61) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL6932477 | 0.85 | NOTUM (0.59) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL21765667 | 0.84 | KMT2A (0.46) | NOTUMALDH1A1SMN1; SMN2HPGDMAPK1 | |
| SCHEMBL7140538 | 0.83 | NOTUM (0.58) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL2636334 | 0.83 | NOTUM (0.58) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL7137753 | 0.82 | NOTUM (0.56) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL23063887 | 0.81 | NOTUM (0.55) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL30520315 | 0.79 | GSK3B (0.53) | ALDH1A1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL9096918 | 0.79 | NOTUM (0.65) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL9136121 | 0.77 | NOTUM (0.63) | NOTUMALDH1A1KDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER IP GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8343987-B2 | Heterocyclic derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-01 | — | — | US | disclosed |
| US-7893073-B2 | Heterocyclic derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20080021053-A1 | Heterocyclic Derivatives | BAYER HEALTHCARE AG (DE) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021053-A1 | Heterocyclic Derivatives | TNNI3, CYP11B2, TNNT2 | NOTUM 2735/4885ALDH1A1 460/4885KDM4E 4443/4885 |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | TNNI3, TNNT2, CYP11B2 | NOTUM 2920/4885ALDH1A1 459/4885KDM4E 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.